Loading...

SOHO 2026 Annual Meeting

This website and third-party tools we use rely on cookies for the best user experience. By selecting "I agree", you agree to cookie usage as described in our Privacy Policy.

1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

ePostersLive by SciGen Technologies S.A. All rights reserved.

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Home Posters by Code Posters by Title Authors Affiliations Topics Sessions Videos Audios Previous meetings

Topics

Select Topic

Showing 71 results for "Myelodysplastic Syndromes (MDS)".

Thumbnail for Defining the Clinicogenomic Footprint of PPM1D in Therapy-Related Myeloid Neoplasms

MDS - 1120

Defining the Clinicogenomic Footprint of PPM1D in Therapy-Related Myeloid Neoplasms

Fidel Cai

Poster Presenter: Fidel Cai

Thumbnail for First-Line (1L) Luspatercept Versus Erythropoiesis-Stimulating Agents (ESAs) for Anemia in Lower-Risk Myelodysplastic Syndromes (LR-MDS): A Real-World Analysis from Florida Cancer Specialists & Research Institute (FCS)

MDS - 1121

First-Line (1L) Luspatercept Versus Erythropoiesis-Stimulating Agents (ESAs) for Anemia in Lower-Risk Myelodysplastic Syndromes (LR-MDS): A Real-World Analysis from Florida Cancer Specialists & Research Institute (FCS)

Amanda Warner

Poster Presenter: Amanda Warner

Previous 1 2 3 4 5...8 Next

Copyright © 2015-2026, ePostersLive® SciGen is a registered trademark of SciGen Technologies S.A. Patent pending.

Thumbnail for Updated Overall Survival (OS) and Long-Term Transfusion Independence (TI) From the Phase 3 COMMANDS Trial in Erythropoiesis-Stimulating Agent (ESA)-Naive Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS)

MDS - 113

Updated Overall Survival (OS) and Long-Term Transfusion Independence (TI) From the Phase 3 COMMANDS Trial in Erythropoiesis-Stimulating Agent (ESA)-Naive Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS)

Guillermo Garcia-Manero

Poster Presenter: Guillermo Garcia-Manero

Thumbnail for Long-Term Safety With Iptacopan Treatment in Patients With Paroxysmal Nocturnal Hemoglobinuria: Pooled Analysis of Data From Phase 2 and 3 Studies and the Roll-Over Extension Program

MDS - 1159

Long-Term Safety With Iptacopan Treatment in Patients With Paroxysmal Nocturnal Hemoglobinuria: Pooled Analysis of Data From Phase 2 and 3 Studies and the Roll-Over Extension Program

Silvia Sanz, Nick Kuypers

Poster Presenter: Nick Kuypers

Thumbnail for Long-Term Hematologic Control and Safety in Patients With Paroxysmal Nocturnal Hemoglobinuria Treated With Iptacopan: 6-Year Follow-Up From Phase 2 Studies and Roll-Over Extension Program

MDS - 1167

Long-Term Hematologic Control and Safety in Patients With Paroxysmal Nocturnal Hemoglobinuria Treated With Iptacopan: 6-Year Follow-Up From Phase 2 Studies and Roll-Over Extension Program

Nick Kuypers

Poster Presenter: Nick Kuypers

Thumbnail for Beyond Platelet Transfusions: Romiplostim Reduces Chemotherapy Dose Modifications in Chemotherapy-Induced Thrombocytopenia: A Meta-Analysis of Randomized Controlled Trials

MDS - 1188

Beyond Platelet Transfusions: Romiplostim Reduces Chemotherapy Dose Modifications in Chemotherapy-Induced Thrombocytopenia: A Meta-Analysis of Randomized Controlled Trials

Hany Dawoud

Poster Presenter: Hany Dawoud

Thumbnail for Whole Genome Sequencing of Patients with Myelodysplastic Syndrome Uncovers Novel, Clinically Relevant Biomarkers Missed by Standard Of Care Methods

MDS - 1210

Whole Genome Sequencing of Patients with Myelodysplastic Syndrome Uncovers Novel, Clinically Relevant Biomarkers Missed by Standard Of Care Methods

Alex Bataller

Poster Presenter: Alex Bataller

Thumbnail for Concurrent DDX41 and TP53 Alterations in Myeloid Neoplasms: Single-Institution Real-World Clonal Dynamics and Outcomes

MDS - 1254

Concurrent DDX41 and TP53 Alterations in Myeloid Neoplasms: Single-Institution Real-World Clonal Dynamics and Outcomes

Ekrem Turk

Poster Presenter: Ekrem Turk

Thumbnail for Comparative Outcomes With Luspatercept Versus Erythropoiesis-Stimulating Agents in Lower-Risk Myelodysplastic Syndromes: A Propensity Score-Matched Retrospective Cohort Study

MDS - 1271

Comparative Outcomes With Luspatercept Versus Erythropoiesis-Stimulating Agents in Lower-Risk Myelodysplastic Syndromes: A Propensity Score-Matched Retrospective Cohort Study

Kumar Anmol

Poster Presenter: Kumar Anmol

ePosters in

Topics Sessions

Acute Lymphoblastic Leukemia (ALL)(71)Acute Myeloid Leukemia (AML)(230)Aggressive B-Cell Lymphoma (ABCL)(114)Cellular Therapy (CT)(128)Chronic Lymphocytic Leukemia (CLL)(110)Chronic Myeloid Leukemia (CML)(55)Hodgkin Lymphoma (HL)(54)Indolent B-Cell Lymphoma (IBCL)(47)Mantle Cell Lymphoma (MCL)(23)Multiple Myeloma (MM)(234)

Previous 1 2 Next

Sponsors